Deckers (DECK) near $81: Is 11x earnings cheap when HOKA growth is slowing?
Deckers Outdoor shares have fallen following weaker sales guidance for HOKA and UGG, despite the company reporting record quarterly revenue and higher earnings. With the stock near $81 and trading at approximately 11 times earnings excluding tariff refunds, the valuation question is whether its premium footwear brands can restore growth without sacrificing profitability.
UCB shares surge as Bimzelx turns a mid-teens outlook into 20%-plus growth
UCB has upgraded 2026 revenue growth to the low twenties and adjusted EBITDA growth to the low-to-mid forties as Bimzelx demand and pricing outperform expectations in the United States.
Union Pacific (NYSE: UNP) profit rises 16% as $7.2bn revenue strengthens Norfolk Southern merger case
Union Pacific reported record quarterly revenue and net income as freight volumes increased 6% and pricing remained firm. Higher fuel costs and the pending Norfolk Southern merger raise questions about future operating efficiency and investment requirements.
L’Oréal sales reach €11.56bn as luxury beauty rebounds and India accelerates
L'Oréal reported third-quarter sales of €11.56 billion and accelerating like-for-like growth as luxury beauty, professional haircare and dermatological products outperformed. Strong demand in India and other emerging markets strengthened its international growth profile.
Bloom Energy (NYSE: BE) near $218: Can 138% growth justify $64bn as cash flow turns negative?
Bloom Energy's quarterly revenue surged 138.1% as demand for AI data centre power accelerated, but the company reported negative free cash flow of approximately $181 million. With shares near $218 and a $64.4 billion equity valuation, the central question is whether rapid expansion can translate into sustainable cash generation without excessive capital spending or dilution.
Moderna (MRNA) falls 18% despite melanoma win: Can an $81bn valuation hold?
Moderna shares plunged 17.57% despite positive Phase 3 melanoma data from its personalised mRNA cancer therapy developed with Merck. With an approximately $81 billion market valuation, continued operating losses and a commercial opportunity extending well beyond melanoma, the central question is how much future oncology success investors have already priced in.
Nokia’s AI network sales jump 123%, but restructuring holds reported margin to 3.8%
Nokia reported €5.15 billion in quarterly sales and a 35% increase in comparable operating profit as AI and cloud customers accelerated network investment. Its widening gap between reported and adjusted profitability remains a key concern.
Barclays profit rises 12% but 19% fixed-income decline tests investment bank strategy
Barclays reported third-quarter pretax profit of £2.32 billion and announced another £500 million share buyback, but a 19% decline in fixed-income trading income overshadowed strong equities performance and growing UK lending.
MS International (AIM: MSI) wins £29.7m German Navy gun systems contract
MS International has secured a £29.7 million order to supply twelve DS30M naval gun systems for Germany's F128 frigate programme, providing new order visibility after a year in which delayed defence procurement affected the company's financial performance.
US Supreme Court allows New Hampshire to ban student IDs for November voting
The U.S. Supreme Court has allowed New Hampshire to enforce restrictions on student IDs as proof of identity when voting, reversing a lower-court intervention shortly before the November midterms.